| LBCTR2020094586 | SEG101A2203 | SEG101A2203 Study Exploring the Effect of Crizanlizumab on Kidney Function in Patients With Chronic Kidney Disease Caused by Sickle Cell Disease | A Phase II, Multicenter, Randomized, Open Label Two Arm Study Comparing the Effect of Crizanlizumab + Standard of Care to Standard of Care Alone on Renal Function in Sickle Cell Disease Patients ≥ 16 Years With Chronic Kidney Disease Due to Sickle Cell Nephropathy | Interventional | Complete | 13/09/2020 |
| LBCTR2019030206 | CICL670F2429 | Safety Study of Crushed Deferasirox Film Coated Tablets in Pediatric Patients With Transfusional Hemosiderosis (MIMAS) | A Single-arm Interventional Phase IV, Post-authorisation Study Evaluating the Safety of Pediatric Patients With Transfusional Hemosiderosis Treated With Deferasirox Crushed Film Coated Tablets | Interventional | Complete | 28/02/2019 |
| LBCTR2022095114 | CLEE011A2412B | Roll-over Study to Allow Continued Access to Ribociclib | A Post-trial Access Roll-over Study to Allow Access to Ribociclib (LEE011) for Patients Who Are on Ribociclib Treatment in Novartis-sponsored Study | Interventional | Complete | 17/08/2022 |
| LBCTR2021104867 | CSEG101A2401B | Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study | An Open-label, Multi-center, Phase IV, Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study | Interventional | Recruiting | 11/10/2021 |
| LBCTR2020011380 | CINC424A2X01B | Rollover An Open Label, Multi-center, Phase IV Rollover Protocol for Patients Who Have Completed a Global Novartis or Incyte Sponsored Ruxolitinib (INC424) or Ruxolitinib and Panobinostat (LBH589) Combination Study and Are Judged by the Investigator to Benefit From Continued Treatment | An open label, multi-center, Phase IV roll-over protocol for patients who have completed a prior global Novartis or Incyte sponsored ruxolitinib (INC424) study and are judged by the investigator to benefit from continued treatment | Interventional | Complete | 02/01/2020 |
| LBCTR2022035014 | TRACE 2020-9591 | Real-World Evidence Study on AbeMaciclib Treatment Patterns and Effectiveness in Patients with HR+/HER2- Locally Advanced or Metastatic BReAst CancEr in Kuwait and Lebanon. | Real-World Evidence Study on AbeMaciclib Treatment Patterns and Effectiveness in Patients with HR+/HER2- Locally Advanced or Metastatic BReAst CancEr in Kuwait and Lebanon. | Observational | Recruiting | 16/03/2022 |
| LBCTR2018090151 | Rasha123 | Rasha 123 | Rasha 123 | Observational | Complete | 15/09/2018 |
| LBCTR2019010169 | LPI-JOR-LEB-KSA-TUN-2017-01 | Randomized, Open-Label, Phase II, Multicenter, Multi-Country Study to Evaluate Safety and Efficacy of Dasatinib 50 mg in First-Line Treatment of Early Chronic Phase Chronic Myeloid Leukemia | Randomized, Open-Label, Phase II, Multicenter, Multi-Country Study to Evaluate Safety and Efficacy of Dasatinib 50 mg in First-Line Treatment of Early Chronic Phase Chronic Myeloid Leukemia | Interventional | Recruiting | 24/10/2018 |
| LBCTR2020011379 | CRAD001T2302 | RADIANT 4 - Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin) | A Randomized, Double-blind, Multicenter, Phase III Study of Everolimus (RAD001) Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced NET of GI or Lung Origin | Interventional | Complete | 02/01/2020 |
| LBCTR2019121361 | HD2305 | Preoperative Chlorhexidine Gluconate Bathing Could Prevent Post-obstetric and gynecologic Surgical-site Infections: A Pilot for a Randomized Controlled Trial | Preoperative Chlorhexidine Gluconate Bathing Could Prevent Post-obstetric and gynecologic Surgical-site Infections: A Pilot for a Randomized Controlled Trial | Interventional | Pending | 24/12/2019 |